To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

The use of cerebrospinal … - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials

Journal article
Authors Bob Olsson
J. M. Schott
Kaj Blennow
Henrik Zetterberg
Published in Expert Review of Neurotherapeutics
Volume 17
Issue 8
Pages 767-775
ISSN 1473-7175
Publication year 2017
Published at Institute of Neuroscience and Physiology
Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
Pages 767-775
Language en
Keywords CSF, biomarkers, clinical trial, Alzheimer's disease, neurodegeneration, creutzfeldt-jakob-disease, csf neurofilament proteins, gamma-secretase, inhibition, mild cognitive impairment, amyloid-beta, total tau, frontotemporal dementia, national institute, double-blind, phospho-tau, Neurosciences & Neurology, Pharmacology & Pharmacy, khann g, 1984, neurology, v34, p939
Subject categories Clinical Medicine


Introduction: All recent phase 3 trials of potentially disease-modifying therapies for Alzheimer's disease (AD) have so far failed. Potential reasons include enrolling subjects whose disease is too advanced or who do not have AD pathology, or simply incorrect drug targets. The goal of disease-modifying AD trials is to halt the progress of neuronal damage and death and this can be assessed in vivo using cerebrospinal fluid (CSF) biomarkers.Areas covered: The authors conducted a literature search of the use of CSF biomarkers in disease-modifying AD clinical trials using PubMed. The authors show that CSF biomarkers have only sparsely been used as outcome measures, and where they have, only in small subsets of patients. No clinical trials have yet showed any substantial effects on CSF biomarkers of neurodegeneration.Expert commentary: In future trials, the authors advocate that CSF biomarkers be used more extensively to optimize the chance of detecting positive drug effects. This includes the identification of potential AD patients - already in the early prodromal stage - for inclusion, for stratification, as readout i.e. proximity markers for changes in axonal/neurodegeneration between treatment and placebo groups - this also enables proof of principle verification in the discovery/dose finding phase, and for monitoring of side effects.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?